Abstract Recent studies suggest that thromboxane (TX) mediates a srgmficant component of anglotensm II (ANG II)-mduced hypertension However, there 1s little information to support the hypotheses that this relationship is important durmg chronic, physrologrcal increases m ANG II, partrcularly whrle controllmg for varratron m endogenous ANG II levels induced by TX mhrbrtron. This study tested that hypothesis m 27 chronically instrumented rats After baseline measurements, suppression of endogenous TX was induced and mamtamed throughout the study m 13 rats by IV mfusron of the TX synthesis mhrbrtor (TSI) U63557A, the other 14 rats received vehicle Baseline mean arterial pressure (MAP) was not different between groups and was unchanged by TSI or vehicle Contmuous mhrbrtron of ANG II production was then mrtrated m both groups of rats by IV mfusron of the angrotensm-convertmg enzyme mhrbrtor (ACEI) benazepril ACE1 reduced blood pressure srmrlarly m vehicle and TSI rats, from 10522 to 9122 mm Hg and 103% 1 to 892 1 mm Hg, respectively ANG II was then infused at 5 ng kg-' mm-' IV for 7 days m SIX rats from each group to restore ANG II actrvrty to baseline levels This dose increased MAP to 10322 and 10121 mm Hg m vehicle and TSI rats, respectively, values not different from pre-ACE1 levels Seven TSI rats and eight vehicle rats received a higher dose of ANG II (20 ng kg-' mn-' IV) After 7 days, MAP was higher m vehicle than in TSI rats ( In acute studies, thromboxane mfusion mhtbits renm release while blockade of thromboxane receptors or mhibmon of thromboxane synthesis stimulates remn secrenon.9 Variation m endogenous levels of ANG II secondary to thromboxane mhibitton could make difficult interpretation of the role of thromboxane per se during ANG II infusion. Therefore, the objective of this study was to determine the role of endogenous thromboxane m 
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Henry L. Keen, Michael W. Brands, Manis J. Smith, Jr, Eugene W. Shek, John E Hall Abstract Recent studies suggest that thromboxane (TX) mediates a srgmficant component of anglotensm II (ANG II)-mduced hypertension However, there 1s little information to support the hypotheses that this relationship is important durmg chronic, physrologrcal increases m ANG II, partrcularly whrle controllmg for varratron m endogenous ANG II levels induced by TX mhrbrtron. This study tested that hypothesis m 27 chronically instrumented rats After baseline measurements, suppression of endogenous TX was induced and mamtamed throughout the study m 13 rats by IV mfusron of the TX synthesis mhrbrtor (TSI) U63557A, the other 14 rats received vehicle Baseline mean arterial pressure (MAP) was not different between groups and was unchanged by TSI or vehicle Contmuous mhrbrtron of ANG II production was then mrtrated m both groups of rats by IV mfusron of the angrotensm-convertmg enzyme mhrbrtor (ACEI) benazepril ACE1 reduced blood pressure srmrlarly m vehicle and TSI rats, from 10522 to 9122 mm Hg and 103% 1 to 892 1 mm Hg, respectively ANG II was then infused at 5 ng kg-' mm-' IV for 7 days m SIX rats from each group to restore ANG II actrvrty to baseline levels This dose increased MAP to 10322 and 10121 mm Hg m vehicle and TSI rats, respectively, values not different from pre-ACE1 levels Seven TSI rats and eight vehicle rats received a higher dose of ANG II (20 ng kg-' mn-' IV) After 7 days, MAP was higher m vehicle than in TSI rats (143?5 versus 12024 mm Hg) These results suggest that endogenous TX IS an rmportant determinant of MAP m ANG II hypertension but may have a dmumshed role m blood pressure regulation when ANG II 1s at normal and subnormal levels (Hypertension. 1997; 29[part 2]:310-314.) Key Words l angrotensm II l thromboxane l blood pressure l hypertensron N umerous interactions exist between thromboxane, a labile cyclooxygenase-dependent metabolite of arachidomc acid, and the remn-angrotensin system Infusion of ANG II stimulates thromboxane production, 1-s and mhtbition of tht-omboxane syntheses attenuates the acute renal and systemic actions of ANG II infusion. 1.2 Furthermore, thromboxane has been suggested to be important in various forms of chronic ANG II-dependent hypertension such as two-kidney, one-clip hypertensive rats6 and the spontaneously hypertensive rat 7
The hypertensive action of thromboxane may be due, in part, to alterations in renal hemodynamics The increase m renal vascular resistance and the development of hypertension in the spontaneously hypertensive rat are almost totally prevented by chronic administration of a thromboxane synthesis mhtbitor. Furthermore, Mtstry et al* have shown that concurrent administration of a thromboxane receptor antagonist attenuated the Increase in renal vascular resistance and the increase in blood pressure caused by the combmatton of high salt diet and mmipump mfusion of high dose ANG II In acute studies, thromboxane mfusion mhtbits renm release while blockade of thromboxane receptors or mhibmon of thromboxane synthesis stimulates remn secrenon.9 Variation m endogenous levels of ANG II secondary to thromboxane mhibitton could make difficult interpretation of the role of thromboxane per se during ANG II infusion. Therefore, the objective of this study was to determine the role of endogenous thromboxane m 
Methods
Male Sprague-Dawley rats weighing 325 to 350 g were used for all experiments Surgery and care of the rats were conducted in accordance wrth National Institutes of Health gmdelmes using protocols approved by the Animal Care and Use Committee of the Umversny of Mrssrss~ppr Medical Center Under pentobarbrtal sodium anesthesia and aseptic conditions, a laparotomy was performed, and a nonocclusrve polyvmyl catheter was Inserted into the abdominal aorta, distal to the krdneys, through a puncture made wrth an 18-gauge needle up The insertron pomt was sealed with cyanoacrylate adhesrve, and the catheter was extenonzed through the lateral abdominal wall A femoral vem catheter was implanted through a separate mcrsron and the tip was maneuvered mto the mfenor vena cava drstal to the kidneys Incrsions were infiltrated with pemctllm G procame and sensorcame, and both catheters were routed subcutaneously to the scapular region and extenorrzed through a stamless steel button that was implanted subcutaneously After recovery from surgery, the rats were placed m mdrvrdual metabolic cages m a quiet, au-condmoned room wrth a 12-hour light cycle The catheters were connected to a dual-channel mfusion swivel (Instech) mounted above the cage and were protected by a stamless steel sprmg The arterial catheter was filled with heparm solutton (1000 USP U/mL) and connected, via the swivel, to a pressure transducer (Cobe) mounted on the cage exterror at the level of the rat Pulsatde artenal pressure signals were sent to an analog-to-drgrtal converter and analyzed by computer using customtzed software The analog signal was sampled 4 seconds each minute, 24 hours per day
The rats received food and water ad hbrtum throughout the study An intravenous mfusron of 20 5 mL sterile 0 9% sahne per day combined with sodium-defictent rat chow, allowed sodmm intake to be clamped at 3 1 mmol/d Independent of food Intake This mfuston was started rmmedrately after placement of the rats m the metabolic cages, and 5 to 7 days were allowed for acch-Selected Abbreviations and Acronyms ANG = anglotensm TX = thromboxane TSI = TX synthesis mh&tor MAP = mean arterial pressure ACE = angiotensm-converting enzyme GFR = glomerular filtration rate PRA = plasma remn actlvlty PG = hrostaglandm ACE1 = ACE mlntntor TGF = tubuloglomerular feedback matlon before control measurements were made All solutions contained antibiohc (pemcdlm G potassmm, 30 000 U/d and mezlocdlm 27 mgld) and were infused mhavenously with a synnge pump (Harvard Apparatus) through a Mdhpore filter (22 pm, Cathivex, Mdhpore)
Experimental Protocol
After a 5-day period durmg which baseline measurements were made, the rats were randomized into two groups The thromboxane synthetase inhibitor U63557A (UpJohn), was added to the mfusate of 13 rats to deliver 30 pg kg-' *mm-' for the remamder of the study This dose of U63557A has been reported to chronically ml&t thromboxane synthetase activity m VIVO 10 The other 14 rats received vehicle After 7 days of TSI or vehicle, endogenous ANG II was suppressed for the remnnder of the study m all rats by a continuous infusion of the convertmg enzyme mhlbltor benazepnl (5 mg kg-'<d-l IV) After 8 days, an ANG II infusion at either 5 ngskg-' mu-' or 20 ng kg-' mu-' was begun and continued for 7 days After stopping the ANG II mfusion, 6 days were allowed for recovery On the third day of the baseline period, and the fifth day of each of the other expenmental periods, 0 6 mL of artenal blood was collected after a 4-hour fast and placed m chilled sodium EDTA tubes for measurement of GFR and effective renal plasma flow (see-discussion of analytical methods below), PRA, hematocnt, and plasma protein concentrations. The sample was replaced with an equal volume of 0 9% salme To measure the urinary excretion of thromboxane Bz and 6-keto-PGFla, urine was collected mto glycme buffer (pH 2 0) on the second day of the baseline period and the fourth day of each of the other expenmental penods Samples were extracted on the same day and were stored at -30°C until assayed Analytical Methods PRA, urinary TXB1, and 6-keto-PGFla concentrations were determined by radlolmmunoassay, plasma protein concentration was measured by refractometry (Amencan Optical, Buffalo, NY), and urinary sodium and potassium concentrations were determined using ion-sensitive electrodes (Nova, Waltham, Mass) GFR and effective renal plasma flow (ERPF) were measured using a 4-hour fasted plasma sample followmg a 24-hour IV mfuslon of [ '251]lothalamate (Glofil) and ['3'I]lodohlppuran Steady state 1s achieved after 24 hours of IV isotope mfuston m this protocol, therefore, urmary excretion rate 1s equal to infusion rate of the isotope and the infusion rate of isotope can be substituted for urinary excretion rate to calculate clearance 11
Data were analyzed with a two-factor analysis of vartance, with repeated measures on one factor (time) Supplemental w&m-group comparisons were made with Dunnett's test and between group comparisons were made wrth unpaired t tests 12
Results

Thromboxane Synthesis Inhibition
Baseline MAP and urinary sodium excretion were not different between the two groups and were unchanged by admmlstratlon of TSI or vehicle. In contrast, GFR mcreased from 2 720 1 to 3.320.1 mL/min, renal plasma flow increased from 7.220.2 to 9 720.5 mL/mm, and PRA increased from 2.720 2 to 3 1 ? 0.2 ng ANG I per mllhhter per hour during TSI admmlstratlon Chronic TSI caused a partial suppression of urinary thromboxane Bz excretion Compared with vehicle rats, this mhlbltlon averaged approximately 60% to 70% (Table 1) . There was no dlfference m excretion of 6-keto-PGFla between the two groups ACE Inhibition ACE inhibition reduced MAP similarly in vehicle and TSIrats,from105t2to9lt2mmHgand103~1to89~1 mm Hg, respectively, and PRA increased markedly from 2.920.1 and 3 120.2 to 55.024.7 and 57 7+7 2 ng ANG I mL-' h-l, respectively. There was no change m urinary sodium excretion or GFR in either group. Renal plasma flow was unchanged m the TSI rats, but tended to increase, although not significantly, from 8.OkO.5 to 9.ltO 5 mL/min m vehicle-treated rats There was no significant change m urinary excretion of 6-keto-PGFla m either group or of thromboxane Bz m TSI rats, however, there was a small but significant reduction in thromboxane B2 excretion in vehicle rats (Table 1) Angiotensin II Infusion at 5 ng m kg-l * min-'
As shown m Fig 1, ANG II infusion at 5 ng * kg-' mn-' increased MAP to 103~2 and lOIt mm Hg m vehicle and TSI rats, respectively, values not different than pre-ACE1 levels. GFR and renal plasma flow were not dlfferent between the two groups prior to the ANG II infusion, and both tended to decrease, although not significantly, durmg the ANG II infusion (Fig 2) PRA was restored to near normal levels, averaging 4 821.2 and 5 5kO.9 ng ANG 1. mL-' * h-' m vehicle and TSI rats, respectively Urinary sodium excretion averaged 2.8kO.2 and 2 7+0 1 mmol/d m vehicle and TSI rats, respectively, and decreased during the first 2 to 3 days of the ANG II mfuslon m both groups before sodium balance was achieved. There was no change m urinary excretion of 6-keto-PGFla m either group, but urmary thromboxane Bz excretion increased approximately 15% in the vehicle rats (Table 2) .
Angiotensin II Infusion at 20 ng -kg-' -min-'
ANG II infusion at 20 ng * kg-' mm-' significantly mcreased MAP slgmficantly m both groups of rats (Fig 3) However, the 19 mm Hg increase m the TSI rats was a significant attenuation compared with the 40-mm Hg mcrease measured m the vehicle rats There were no dlfferences m GFR or renal plasma flow between the two groups prior to the ANG II infusion, and GFR was not changed by ANG II infusion (5 ng kg-' mln-' Iv) PRESSURE 100 -(mm+b) TIME (days) with this dose of ANG II in either group (Fig 4) Renal plasma flow decreased m both groups of rats, however, the reduction was statlstlcally slgmficant only m the vehicle rats PRA was suppressed to 0.3920.12 and 0 4720.11 ng ANG I.mL-'a h-' m vehicle and TSI rats, respectively. Urinary sodium excretion fell on day 1 of the ANG II mfuslon in both groups and sodium balance was restored by day 2. Urinary excretion of 6-keto PGF la mcreased significantly m both groups, but excretion of thromboxane B2 mcreased only m the vehicle rats (Table 2 ).
Discussion
The mam findings from this study are that thromboxane 1s an important mediator of the hypertensive response to chronic, physiological increases m ANG II, but may play a lessor role m regulation of blood pressure when ANG II 1s at normal or reduced levels Previous studies have shown that thromboxane synthe-SIS mhlbltors or receptor antagonists do not affect blood pressure under basal condltlons '-3~ However, interpretation of those studies 1s complicated by the fact that thromboxane synthesis mhlbltion increases PRA9 and, presumably, endogenous levels of ANG II. This increase m ANG II then might offset any potential blood pressure-lowering action of thromboxane mhlbltlon. To address this issue, ANG II levels were clamped at normal m the present study by chrome converting enzyme inhibition and IV infusion of ANG II at a rate that returned ANG II actlvlty (assessed by steady state MAP) to control levels. Under these condltlons, with ANG II held constant, there still was no effect of chrome TSI on blood pressure This evidence suggests that thromboxane 1s not a major regulator of blood pressure under basal condltlons. In addition, the slrmlar blood pressure reduction m TSI and vehicle rats given ACE1 alone suggests that TX does not have an important effect on blood pressure when ANG II 1s low However, since chronic TSI only partially reduced urinary thromboxane excretion (60% to 70%), it 1s possible that the remammg thromboxane may have had an effect on blood pressure which would have been revealed by more complete inhrbitron of thromboxane synthesis. In contrast to those results, when ANG II levels were increased above normal, blood pressure was significantly higher m vehicle rats compared with TSI rats Thus suggests that full expression of ANG II hypertension requires an intact ability to synthesize thromboxane However, because mhtbrtron of thromboxane synthetase has been suggested to redirect prostaglandm endoperoxtdes mto enzymatrc pathways for vasodrlatory PGs,13 another explanation is that these vasodtlatory PGs were responsible for the attenuated increase m blood pressure assoctated wtth TSI. In support of this possrbrhty, furosemrde-stimulated renal prostaglandm productron 1s enhanced by pretreatment with a thromboxane synthetase mhtbttor 13 present study, there was a significant increase in urmary excretion of 6-keto-PGFla, the stable hydrolyses product of PG12, durmg the high dose ANG II mfusron However, there was no difference in urinary excretton of 6-ketoPGFla between the two groups, suggesting that PGI? levels were not affected by TSI m this study. In addttton, because the TSI dose was constant throughout the study, any potential strmulatory effect on synthesis of vasodtlator PGs that might influence blood pressure also should have been present throughout, However, there was no mdrcatton that this potential mechanism had any effect on blood pressure. Another potential factor that could have influenced these results is an alteration m bradykmin metabohsm secondary to ACE mhrbmon However, smce both groups of rats were treated with the same fixed dose of ACE mhtbrtor throughout the study, tt 1s unlikely that the differential blood pressure response between vehrcle and TSI rats was due to a difference m bradykmm metabohsm, although this possrbrhty can not be completely ruled out Moreover, there was a clear effect of urinary thromboxane B2 levels to vary directly with ANG II levels, but only m the vehicletreated rats and only markedly at the ANG II mfuston dose that increased ANG II activity above normal. Thus suggests, therefore, that the attenuated ANG II hypertension m the TSI rats was due to a reductton m ANG II-sttmulated thromboxane synthesis.
The mechanism through which thromboxane potentiates the hypertensive action of ANG II IS not known Thromboxane is known to have both vascular and tubular actions. 14 One posstbrhty is that thromboxane interacts wtth ANG II at a tubular site However, the tubular actions of ANG II predominate m the lowest effective concentration range, i5 and the stmtlar changes m blood pressure m vehicle and TSI rats m response to ACE1 and to restoration of normal ANG II actrvrty suggests that thromboxane did not have a srgmficant effect on the tubular actions of ANG II. With increased ANG II levels, the renal vascular actions are of increased rmportance,r5 and this was confirmed by the srgmficant decrease m renal plasma flow measured with ANG II hypertension However, this effect was srgmficantly greater m the vehicle rats. Thus, the effect of TSI to attenuate ANG II mduced renal vasoconstrrctlon and the increase m blood pressure suggests that throm-boxane potentiated the hypertensive action of ANG II via interaction primarily at a vascular site ANG II 1s known to construct the afferent arteriole mdirectly by activation of the TGF mechanism I6 Furthermore, thromboxane also has been shown to potentlate TGF while thromboxane synthesis mhibmon markedly attenuates this response.17 It is posstble, therefore, that thromboxane could interact with ANG II at the macula densa to activate TGF and constrict the afferent arteriole However, m the present study, the maintenance of GFR with a stgmficant fall m renal plasma flow suggests that the predommate site of vasoconstriction is the efferent arteriole Although most studies have shown the predommate site of constrlctlon for exogenously administered thromboxane to be the afferent arteriole, 18 Tucker et alI9 reported that mhibttion of endogenous thromboxane synthesis caused a reduction m both afferent and efferent artenolar reststance This provides evidence that the direct effect of ANG II to constrict the efferent arteriole could be influenced by thromboxane Thus, these results suggest that ANG II levels increased wlthm the physlologlcal range cause an increase m blood pressure that is mediated significantly through the effect of ANG II to increase thromboxane synthesis However, the importance of thromboxane m determmmg the blood pressure and renal hemodynamtc response to ANG II may be dtmmished when ANG II is at normal or reduced levels In addmon, these results suggest that the effect of thromboxane to potentlate the hypertensive action of ANG II may be due to mteraction with ANG II m the control of renal vascular reststance, possibly at the level of the efferent arteriole
